Last reviewed · How we verify
Metformin Small Pack
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, thereby lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin Small Pack |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that activates AMP-activated protein kinase (AMPK), which suppresses gluconeogenesis in the liver and enhances glucose uptake and utilization in muscle and adipose tissue. It does not stimulate insulin secretion, making it weight-neutral and suitable for use across a range of patient populations. The 'Small Pack' designation refers to a lower-dose or smaller-quantity formulation for convenient dosing.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency (with long-term use)
- Lactic acidosis (rare, in renal impairment)
Key clinical trials
- An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes (PHASE4)
- Diabetic Treatment Adherence
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin Small Pack CI brief — competitive landscape report
- Metformin Small Pack updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI